Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Adjuvant chemotherapy in NSCLC 종양혈액내과 이재진 우리나라 암발생률 1999-2001 보 건 복 지 부 2005. 4. 27 암 발생 통계 연도 남자 여자 계 1999년 57,687 43,202 100,889 2000년 57,417 43,050 100,467 2001년 61,927 47,432 109,359 계 177,031 133,684 301,715 연평균발생건수 59,010 44,561 103,571 성별 암종별 발생분율 남자 여자 기타 16.7% 위 23.7% 비호지킨 림프종 2.1% 전립선 2.4% 위 16.4% 기타 18.7% 췌장 2.5% 췌장 2.7% 난소 3.0% 담낭 2.7% 담낭 3.5% 2 식도 2.8% 방광 3.1% 대장 9.8% 폐 17.0% 유방 13.7% 갑상선 6.7% 5 간 7.3% 간 17.0% 폐 8.0% 대장 10.4% 자궁경부 9.8% Incidence and Survival of Lung Cancer 2002년 한국중앙암등록본부 위 20.2% 기타 21.9% 폐 20.0% 기타 20.5% 자궁경부 1.6% 방광 2.2% 폐 11.9% 췌장 2.4% 조혈계 2.6% 수막, 뇌 및 기타 중 추신경계 1.9% 유방 2.2% 위 18.7% 백혈병 2.3% 자궁경 4.0% 식도 2.4% 갑상선 4.9% 유방 7.4% 간 11.3% 대장 11.2% 2002년, 발생율 † 췌장 4.6% 대장 8.1% 간 17.7% 2002년, 사망분율 ‡ Screening test for early detection of Lung caner • Low dose chest CT • Sputum cytology • Chest X-ray Disease stage at diagnosis of Lung caner Disease stage at diagnosis 5-year survival To improve the survival of lung cancer, Minimize the relapse of lung cancer at curative setting Rationale for adjuvant chemotherapy - Disease recurrence Stage Chest Distant Stage I 55-65 % T1N0 10 % 15 % T2N0 10 % 30 % Stage II T1-2N1 40-55 % 12 % 40 % Stage IIIA N2 5YS 20-25 % 15 % 60 % Feld 1984; Pairolero 1984; Mqrtini 1980; Thomas 1990 Rationale for adjuvant chemotherapy - Theoretical premises • An inverse relationship between cell number and curability – Skipper HE et al. Cancer Chemother Res 1964;35:1 • Larger fractional kill in smaller tumors that have larger growth fraction – Norton LA. Cancer Res 1988;48:7067 • Drug resistant cells emerge as tumor burden increases – Goldie JH et al. Cancer Treat Rep 1979;63:1727 Rationale for adjuvant chemotherapy - Theoretical premises (Mo) (Mo) Cancer medicine 6th edition Rationale for adjuvant chemotherapy - Theoretical premises Systemic therapy will be more effective in the setting of minimal residual tumor Survival benefit of adjuvant chemotherapy in other solid tumors • Early breast cancer – 3.2% at 5Y, 6.3% at 10Y • Early ovarian cancer – 8% at 5Y • Duke’s class C colon cancer – 5% at 3Y • Limited stage SCLC (by RT & PCI) – 5.4% at 3Y Evidence-based medicine Level and Grade of evidence for recommendations Clinical trial of Adjuvant chemotherapy 0. A British Medical Research Council, NSCLC Collaborative Group – Meta-analysis, N=4457, 17 trials (BMJ 1995;311:899-909) – Nonsignificant 5 percent absolute increase (stage I,II,III) (p=0.08) 1. 2. 3. 4. 5. 6. The International Adjuvant Lung Cancer Trial (IALT) The Adjuvant Lung Project Italy-EORTC (ALPI) The Adjuvant Navelbine International Trialist Association (ANITA) The Big Lung Trial (BLT) National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) JBR.10 trial Lung Adjuvant Cisplatin Evaluation (LACE) – 7. 8. Meta-analysis, N=4584, 5 trials (2006 ASCO Annual Meeting) CALGB protocol 9633 trial/ CALGB protocol 9633 trial The Japanese Lung Cancer Research Group Concern in adjuvant setting • Elderly patients • Surgery type, i.e., pneumonectomy • Adjuvant RT • What regimen • Compliance, i.e., planned dose The International Adjuvant Lung Cancer Trial (IALT) • The effect of cisplatin-based adjuvant CTx on survival ? – 3 or 4 cycles of cisplatin-based CTx vs. observation • Etoposide, vinorelbine, vinblastine, vindesine – 1867 pts: 932 pts (CTx) vs.935 pts (Obs) • Stage I, stage II, stage III • 1995/2 - 2000/12/31 • European • Early termination (N=3,300 pts) d/t slow enrollment ← neoadjuvant CTx NEJM 2004;350:351-60 The International Adjuvant Lung Cancer Trial (IALT) NEJM 2004;350:351-60 The International Adjuvant Lung Cancer Trial (IALT) Median F/U: 56 months 5Y OS: 44.5% vs. 40.4% 5Y DFS: 39.4% vs. 34.3% Overall survival Disease free survival HR 0.86 HR 0.83 Survival Benefit (+) (95% CI, 0.76-0.98, p<0.03) (95% CI, 0.74-0.94, p<0.003) NEJM 2004;350:351-60 The International Adjuvant Lung Cancer Trial (IALT) • Compliance – Planned dose: 73.8% of pts – The chief reasons for incomplete treatment • Adverse effects: 51.5% • Pts or physician’s refusal: 24.3% • PD: 5.1% – Adjuvant RT; 31% of pts • Planned therapy: 70.4% in chemotherapy vs. 84.2% in control group • Acute adverse effects – Treatment-related death: 0.8% (7pts) • BM aplasia, renal failure, hyponatremia – Any grade 4 toxicity: 22.6% of the patients NEJM 2004;350:351-60 The Adjuvant Lung Project Italy-EORTC (ALPI) • The effect of cisplatin-based adjuvant CTx on survival ? – 3 cycles of cisplatin-based CTx vs. observation • mitomycin, vindesine, cisplatin (MVP regimen) – 1209 pts: 606 pts (CTx) vs. 603 pts (Obs) • Stage I, II, IIIA • 1994/1-1999/1 • European J Natl Cancer Inst 2003;95:1453-61 The Adjuvant Lung Project Italy-EORTC (ALPI) J Natl Cancer Inst 2003;95:1453-61 The Adjuvant Lung Project Italy-EORTC (ALPI) Median F/U: 64.5 months 5Y survival benefit: 1% 5Y DFS benefit: 4% Median; 55.2m vs. 48m Median; 36.5m vs. 28.9m Overall survival Disease free survival HR 0.96 HR 0.89 Survival Benefit (-) (95% CI, 0.81-1.13, p=0.589) (95% CI, 0.76-1.03, p=0.128) J Natl Cancer Inst 2003;95:1453-61 The Adjuvant Lung Project Italy-EORTC (ALPI) • Compliance – Planned dose: 69% of pts – The chief reasons for incomplete treatment, 110 pts (22%) • Adverse effects: 60% • Pts refusal: 40% – Adjuvant RT; 43% of pts • 65% in chemotherapy vs. 82% in control group • Acute adverse effects – Treatment-related death: 0.5% (3pts) – Grade 3/4 neutropenia: 16%/12% of the patients – Grade 3/4 N/V: 13%/4% of the patients J Natl Cancer Inst 2003;95:1453-61 ANITA Trial • The effect of cisplatin-based adjuvant CTx on survival ? – 4 cycles of vinorelbine plus cisplatin vs. observation – 840 pts: 407 pts (CTx) vs. 433 pts (Obs) • Stage IB, stage II, stage IIIA • 1995/2 - 2000/12/31 • European Lancet Oncol 2006;7:719-27 ANITA Trial Lancet Oncol 2006;7:719-27 ANITA Trial Median F/U: 76 months 5Y OS: 8.6% benefit 0 20 40 60 80 5Y DFS: 8.7% benefit 100 (M) Overall survival Disease free survival HR 0.80 HR 0.76 Survival Benefit (+) (p=0.017) (p=0.002) Lancet Oncol 2006;7:719-27 ANITA Trial • Compliance – Planned dose: 50% of pts • Dose intensity; vinorelbine (59%), cisplatin (89%) • 3 or more cycles: 61% of pts – Adjuvant RT; 28% of pts • Acute adverse effects – Treatment-related death: 2% (7pts) – G3/4 toxicity: fatigue (28%), nausea (27%), FN (9%), neuropathy (3%) Lancet Oncol 2006;7:719-27 Big Lung Trial (BLT) • The effect of cisplatin-based adjuvant CTx on survival ? – 3 cycles of cisplatin-containing regimen vs. observation • Vindesine, mitomycin & ifosfamide, mitomycin & vinblastine, vinorelbine – 381 pts: 192 pts (CTx) vs. 1893 pts (Obs) • Stage IB, stage II, stage III, stage IV • Adjuvant setting, 97% (neoadjuvant setting 3%) • 1995/11 - 2001/11 • UK • Early closure d/t slow accrual & ceased funding Eur J Cardiothorac Surg 2004;26:173-82 Big Lung Trial (BLT) • Complete resection Extra information; R0, 15 pts R1, 21 pts R2, 8 pts True complete resection rate: 95% • Median duration to start of CTx: 7 wks Eur J Cardiothorac Surg 2004;26:173-82 Big Lung Trial (BLT) Median F/U: 34.6 months 2Y OS: 58% vs. 60% Median, 33.9m vs. 32.6m 2Y DFS: 53% vs. 51% Median, 27m vs. 24.7m (Mo) (Mo) Overall survival Disease free survival HR 1.02 HR 0.97 Survival Benefit (-) (p=0.90) (p=0.81) Eur J Cardiothorac Surg 2004;26:173-82 Big Lung Trial (BLT) • Compliance – Planned dose: 64% of pts • 21% of pts: early termination – Cause: pts’ and physician decision (49%), toxicity (34%), death, PD • 13% of pts: no chemotherapy – Cause: death, refusal, poor condition – Adjuvant RT; 14% of pts • Acute adverse effects – Treatment-related death: 3.1% (6pts) – Any G3/4 toxicity: 30%, hematologic, N/V, FN Eur J Cardiothorac Surg 2004;26:173-82 NCIC CTG JBR. 10 trial • The effect of adjuvant vinorelbine plus cisplatin on survival ? – 4 cycles of vinorelbine plus cisplatin vs. observation – 482 pts: 242 pts (CTx) vs. 240 pts (Obs) • Stage IB, stage II (except, T3N0) • 1994/4 - 2001/4 • CALGB, SWOG, ECOG joined in 1998 • Canadian and American NEJM 2005;352:2589-97 NCIC CTG JBR. 10 trial NEJM 2005;352:2589-97 NCIC CTG JBR. 10 trial Median F/U: 63 months 5Y OS: 69% vs. 54% 5Y DFS: 61% vs. 49% Overall survival Disease free survival HR 0.69 HR 0.60 Survival Benefit (+) (p=0.009) (p<0.001) NEJM 2005;352:2589-97 NCIC CTG JBR. 10 trial 7% benefit 20% benefit NEJM 2005;352:2589-97 NCIC CTG JBR. 10 trial • Compliance – Planned dose: 48% of pts • Median cycle: 3 • 3 or more cycles: 58% of pts – 32% of patients required hospitalization • 7% for chemotherapy • 6% for unrelated treatment • 19% for medical problem related to toxicity – Adjuvant RT (-) • Acute adverse effects – Treatment-related death: 0.8% (2pts) – G3/4 toxicity: fatigue (15%), nausea (10%), FN (7%) – G3/4 neurotoxicity: hearing loss (2%), sensory & motor (5%) NEJM 2005;352:2589-97 Lung Adjuvant Cisplatin Evaluation (LACE) • Meta-analysis – 5 Randomized Trials – 4,584 patients – Inclusion • Sample size >300 • Cisplatin-based chemotherapy – Median F/U; 5.1 years (3.1-5.9) 2006 ASCO Annual Meeting Lung Adjuvant Cisplatin Evaluation (LACE) Overall survival HR 0.89 (p=0.004) Survival Benefit (+) 2006 ASCO Annual Meeting Lung Adjuvant Cisplatin Evaluation (LACE) 3.9% 5.3% Overall survival Survival Benefit (+) 2006 ASCO Annual Meeting Lung Adjuvant Cisplatin Evaluation (LACE) Cisplatin-based chemotherapy is effective for stages II & III 2006 ASCO Annual Meeting Lung Adjuvant Cisplatin Evaluation (LACE) The effect of cisplatin + vinorelbine was marginally better than that of other drug combination (p=0.04, post-hoc analysis) 2006 ASCO Annual Meeting CALGB protocol 9633 trial • The effect of adjuvant paclitaxel plus carboplatin on survival ? – 4 cycles of paclitaxel plus carboplatin vs. observation – 344 pts: 173 pts (CTx) vs. 171 pts (Obs) • Stage IB • 1996/9 - 2003/11 • American • Early closure d/t slow accrual & ceased funding JCO 2004;22:14S, ASCO abstract JCO 2006;24:18S, ASCO abstract CALGB protocol 9633 trial • Patients’ characteristics – Age; 61 yr (34-81) – M;F=64%;36% – Surgery • Lobectomy; 89% JCO 2004;22:14S, ASCO abstract JCO 2006;24:18S, ASCO abstract CALGB protocol 9633 trial Median F/U: 34 months 3Y OS: 79% vs. 71% Overall survival HR 0.62 (p=0.028) Median F/U: 54 months 5Y OS: 59% vs. 57% Overall survival HR 0.80 (p=0.32) Disease free survival HR 0.69 (p=0.035) Disease free survival HR 0.74 (p=0.027) Survival Benefit (+) Survival Benefit (-) JCO 2004;22:14S, ASCO abstract JCO 2006;24:18S, ASCO abstract CALGB protocol 9633 trial 3Y OS: 79% vs. 71% 5Y OS: 59% vs. 57% Survival Benefit (+) Survival Benefit (-) JCO 2004;22:14S, ASCO abstract JCO 2006;24:18S, ASCO abstract CALGB protocol 9633 trial Survival Benefit (+) DFS Benefit (+) JCO 2004;22:14S, ASCO abstract JCO 2006;24:18S, ASCO abstract CALGB protocol 9633 trial • Compliance – Planned cycle: 84% of pts – 33% of patients required dose modification • Acute adverse effects – Treatment-related death: 0% – G3/4 neutropenia; 36% of pts JCO 2004;22:14S, ASCO abstract JCO 2006;24:18S, ASCO abstract The Japanese Lung Cancer Research Group • The effect of Uracil-tegafur adjuvant CTx on survival ? – oral uracil-tegafur for 2 years vs. observation – 979 pts: 491 pts (CTx) vs.488 pts (Obs) • pT1N0, pT2N0 (stage I) • Adenocarcinoma • 1994/1 - 1997/3 NEJM 2004;350:1713-21 The Japanese Lung Cancer Research Group NEJM 2004;350:1713-21 The Japanese Lung Cancer Research Group Median F/U: 73 months 5Y OS: 88% vs. 85% 5Y OS: 85% vs. 74% Overall survival Overall survival with T2 disease HR 0.71 HR 0.48 Survival Benefit (+) (p=0.04) (p=0.005) NEJM 2004;350:1713-21 The Japanese Lung Cancer Research Group • Compliance – Planned dose: 74% of pts at 1Y, 61% at 2Y – The chief reasons for incomplete treatment • Adverse effects: 123 pts • Patient’s refusal: 52 pts • Physician’s decision: 34 pts • Acute adverse effects – Any grade 3 toxicity: 2% of the patients • Anorexia, nausea, diarrhea, increase of ALT NEJM 2004;350:1713-21 Phase III trial Trial When N Regimen RT Stage 31 % I,II,III 4.1% Nation TRD Subgroup analysis <0.03 Europe 0.8% - 5YS (+) P-value IALT 95 1867 P+ VNR,VBL, VDS,VP-16 ALPI 94 1209 P+ MMC+VDS 43 % I,II,III 1% 0.589 Europe 0.5% - ANITA 95 840 P+ VNR 28 % IB,II,IIIA 8.6% 0.017 Europe 2% N1,N2 (+) BLT 95 381 P+ VDS,MI, MV,VNR 14 % IB,II,III 2Y, -2% 0.90 UK 3.1% - JBR.10 94 482 P+ VNR - IB,II 15% 0.009 Canada USA CALGB 96 344 CbTx - IB 3Y,8% 5Y,2% 0.028 0.32 USA 0% T>4cm(+) Japan 94 979 Tegafur - I,adenoca 3% 0.04 Japan 0% T2(+) 0.8% Stage II(+) Survival benefit • Worldwide 75세 미만; 900,000/yr, Lung cancer Dx 80% NSCLC; 720,000 1/3 resectable; 240,000 75% adjuvant chemotherapy Ix: 180,000 4% survival benefit; 7000/yr safe • 한국 75세 미만; 11,000/yr, Lung cancer Dx 80% NSCLC; 9,000 1/3 resectable;3,000 75% adjuvant chemotherapy Ix: 2,500 4% survival benefit; 100/yr safe Standard therapy of resectable NSCLC Harrison, 16th Edition: • Surgical resection for stage IA, IB, IIA, IIB, some IIIA • Surgical resection with complete-mediastinal LN dissection RecommendofCisplatin-based chemotherapy stage II &patients III NSCLC. • Discussion risks/benefits adjuvant of adjuvant Ctx withinfor individual Consider cisplatin-based adjuvant chemotherapy for stage IB. - size, age, surgery type etc. Limitation • Compliance – Age, pneumonectomy • QoL – Fatigue, N/V • A large proportion of patients with cancer – without any benefit • Toxic effects of treatment – TRD: below 1.0 % Major issue of adjuvant chemotherapy • Poor compliance – LCSG 772: cumulative dose: 58% of the scheduled dose – LCSG 791: only 51% of pts as scheduled dose – NCIC CTG BR.10: only 50% of pts as scheduled dose Lung Cancer 2005;47:385-94 Compliance of adjuvant chemotherapy Lung Cancer 2005;47:385-94 평균수명까지 생존 시 암에 걸릴 확률은 ? 평균수명 (2000년) 암에 걸릴 확률 72.8세 80.1세 74세까지 누적위험 29.0% 80세까지 누적위험 20.2% 약 3명 중 1명 약 5명 중 1명 Major issue of adjuvant chemotherapy • Adjuvant chemotherapy in elderly patients, NCIC-CTG JBR.10 – West • >65 years: more than 50% • >70 years: 30-40% – Korea >65 years: 54.7% >70 years: 34.0% JCO 2007;25:1553-61 Adjuvant chemotherapy in elderly patients JCO 2007;25:1553-61 Adjuvant chemotherapy in elderly patients Overall survival, age> 65 years JCO 2007;25:1553-61 Impact of adjuvant chemotherapy in Elderly patients • Adjuvant CTx improves survival in patients older than 65 years with acceptable toxicity • Adjuvant CTx should not be with held from elderly patients QoL of adjuvant chemotherapy • NCIC CTG BR.10 with EORTC QLQ-C30 – Observation arm: improvement in QoL by 3 months – Chemotherapy arm: Rapidly resolved within 3 months after completion of CTx 80 70 60 50 40 30 20 10 0 Global QoL Role function Physical function fatigue pain dyspnea sleep cough • BLT with EORTC QLQ-C30 shortness of breath worry about health Baseline (post-op) – No evidence to suggest a detrimental effect on QoL from the use of CTx • LCSG 801, 853 with FLIC (functional living index-C) Impact of adjuvant chemotherapy on QoL • No significant impact of a short course of chemotherapy on QoL • If any side effect, rapidly resolved Conclusion • Recommend adjuvant chemotherapy for stage II and III • Consider adjuvant chemotherapy for stage IB – Especially, T>4cm • Elderly patients are no contraindication for adjuvant chemotherapy • QoL may be rapidly resolved by 3 months after adjuvant therapy